Who are Naltrexone plus Gabapentin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naltrexone-plus-gabapentin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Naltrexone plus Gabapentin — Competitive Intelligence Brief

Naltrexone plus Gabapentin (Naltrexone plus Gabapentin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist + anticonvulsant/analgesic combination. Area: Psychiatry/Addiction Medicine.

phase 3 Opioid antagonist + anticonvulsant/analgesic combination Opioid receptors (mu, delta, kappa) + voltage-gated calcium channels (Cav2.1, Cav2.2) Psychiatry/Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Naltrexone plus Gabapentin (Naltrexone plus Gabapentin) — Medical University of South Carolina. Naltrexone blocks opioid receptors while gabapentin modulates calcium channels and GABA neurotransmission to reduce pain and cravings in opioid use disorder.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naltrexone plus Gabapentin TARGET	Naltrexone plus Gabapentin	Medical University of South Carolina	phase 3	Opioid antagonist + anticonvulsant/analgesic combination	Opioid receptors (mu, delta, kappa) + voltage-gated calcium channels (Cav2.1, Cav2.2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist + anticonvulsant/analgesic combination class)

Medical University of South Carolina · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naltrexone plus Gabapentin — Competitive Intelligence Brief. https://druglandscape.com/ci/naltrexone-plus-gabapentin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab